Brain's 'Pain Switch' Found - Estaw

In a groundbreaking discovery that could revolutionize pain management, researchers have identified a neural “pain switch” in the brain that may lead to safer, more targeted medications. This discovery centers around an enzyme called VLK (Vertebrate Lonesome Kinase), which acts as a critical regulator for pain perception and could be the key to developing alternatives to current opioid-based pain medications.

The Discovery of a Neural Pain Switch

Researchers at Tulane University in New Orleans have uncovered a novel mechanism in the brain that flips on a “pain switch” through a process that occurs outside the cell—a significant departure from traditional understanding of how pain receptors work.

The discovery revolves around phosphorylation, a biochemical process where an enzyme modifies another protein’s function. In this case, the VLK enzyme is released by neurons and modifies proteins on the outside of other cells, effectively turning on pain signaling.

“This is one of the first demonstrations that phosphorylation can control how nerve cells communicate outside the cell,” explained Dr. Matthew Dalva, director of the Tulane Brain Institute and professor of cell and molecular biology at Tulane University. “The fact that removing VLK in mice reduced pain sensitivity without affecting normal movement is particularly noteworthy.”

How VLK Works

The VLK enzyme functions through extracellular phosphorylation to control neuron signaling related to pain. Specifically:

Neurons release VLK outside the cell
VLK modifies proteins in the space between neurons
This modification affects how cells send pain signals
The process is a form of phosphorylation that alters protein function

In experiments with mice, researchers manipulated VLK levels to observe its effects on pain perception. When they removed VLK from pain-sensing neurons, the animals did not feel the usual pain after surgery but continued to move and sense normally. Conversely, adding more VLK heightened pain sensitivity.

The Quest for Safer Pain Medications

This discovery holds tremendous promise for developing pain treatments that are both safer and more effective than current medications like opioids. The opioid crisis in the United States has reached epidemic proportions, with approximately 80,391 drug overdose deaths reported in 2024 alone according to the CDC’s National Center for Health Statistics.

Current pain medications often come with severe side effects and addiction potential. Opioids, while effective for pain relief, can lead to dependence, tolerance, and in many cases, fatal overdose. The CDC reports that synthetic opioids other than methadone—including fentanyl—continue to be involved in the majority of opioid overdose deaths.

Comparison with Current Treatments

The VLK discovery offers several advantages over existing pain medications:

Targeted Mechanism: VLK works specifically on pain signaling pathways outside the cell
Reduced Side Effects: Early research shows VLK manipulation doesn’t impair normal movement or sensation
Lower Addiction Risk: The mechanism doesn’t appear to involve the reward pathways that contribute to opioid addiction
Precise Control: The external nature of the signaling makes it potentially easier to target with medications

“Instead of blocking receptors at synapses—which can result in side effects—we might have an easier go at delivering pain relief by targeting enzymes like VLK,” noted researchers in the field.

Tulane University’s Leading Role

The significant research leading to this discovery was conducted at Tulane University in New Orleans, specifically at the Tulane Brain Institute. Under the leadership of Dr. Matthew Dalva, the research team has been investigating how the connections of the brain form and are changed by experience.

Tulane University has a strong neuroscience program, established as the school’s first interdisciplinary doctoral program in 1986. The Brain Institute represents the educational and training arm of this program, conducting cutting-edge research in cellular and molecular neuroscience.

The research involved collaboration with multiple universities and was published after extensive peer review, adding credibility to the findings. The study specifically tested whether a secreted kinase could control the interaction between the receptor tyrosine kinase EphB2 and NMDA receptors, a key pathway in pain signaling.

Broad Implications for Pain Management

The discovery addresses the universal and critical need for better pain management. Chronic pain affects approximately 20% of adults in the United States, with many struggling to find effective relief without severe side effects.

The NIH HEAL Initiative has identified pain management research as a core goal in addressing the national opioid crisis. Established in 2018, the HEAL (Helping to End Addiction Long-term) Initiative has funded nearly 1,200 research projects focused on pain and addiction research across all 50 states.

Potential Applications

This discovery could impact several areas of pain management:

Post-surgical pain: Targeting VLK could provide effective relief without the risks associated with current medications
Chronic pain conditions: The mechanism might be applicable to various chronic pain disorders
Neuropathic pain: The extracellular signaling pathway may be particularly relevant for nerve-related pain
Pediatric pain management: Safer medications could benefit children who are particularly vulnerable to opioid side effects

The research also opens new avenues for understanding how pain develops and persists. By identifying an external mechanism for pain signaling, scientists may discover additional targets for therapeutic intervention.

Looking Ahead

While the discovery is promising, developing new medications based on this research will take time. The process from laboratory discovery to FDA-approved medication typically takes a decade or more, involving multiple phases of clinical trials to ensure safety and efficacy.

Researchers are now working to understand the full scope of VLK’s role in pain signaling and to identify compounds that could safely modulate its activity in humans. The fact that this mechanism works outside the cell is particularly encouraging, as extracellular targets are often easier to reach with medications than intracellular ones.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development and other NIH institutes are actively supporting research into non-opioid pain management approaches, including studies that build on findings like the VLK discovery.

Conclusion

The identification of VLK as a “pain switch” represents a significant advancement in our understanding of how pain is processed in the brain. By working outside the cell to modify proteins and trigger pain signaling, this enzyme offers a novel target for therapeutic intervention.

While much work remains before VLK-targeted medications reach patients, the discovery provides hope for millions of people suffering from chronic pain who are seeking safer alternatives to current treatments. As researchers continue to unravel the complexities of pain signaling, findings like this one from Tulane University bring us closer to a future where effective pain relief doesn’t come with the risk of addiction or severe side effects.

For a condition that affects such a significant portion of the population, any advance toward safer, more effective treatments represents meaningful progress. This discovery adds an important piece to the puzzle of pain management, with the potential to benefit patients, healthcare providers, and society as a whole.

Sources:

Brain’s ‘Pain Switch’ Found